Clinical trials: Adjuvant Drug Therapy
Breast Cancer
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002679
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Yale University
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Tislelizumab), targeted therapy (Cetuximab), with chemotherapy (Cisplatin and Nab-paclitaxel) as a possible…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT06728618)
- Testing
- Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer, Stage I Breast Cancer
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can…
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00146562
- Testing
- Darbepoetin Alfa, Pegfilgrastim, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- Harold J. Burstein, MD, PhD
Esophageal Adenocarcinoma
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate…
- Trial name
- RICE (NCT04159974)
- Testing
- Durvalumab 50 MG/ML, Tremelimumab
- Where
- 2 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University of Cologne
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer, Primary Peritoneal Cavity Cancer
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- COCHISE (NCT00766142)
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Bergonié
Colonic Diseases, Adenocarcinoma
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer
Based on the astonishing high response rate in metastatic colorectal cancer in weekly high dose 5-FU and leucovorin, we will conduct a clinical trial to clarify the activity of this regimen in the adjuvant setting.
- Trial name
- NCT00201331
- Testing
- leucovorin+5-FU
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- National Health Research Institutes, Taiwan
Colorectal Neoplasms
Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer
Subgroups of patients with radically operated colorectal cancer can have a better prognosis by over six months are treated with chemotherapy.
- Trial name
- NCT02412683
- Testing
- oxaliplatin
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Jenny Drott
Lymphoma
Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.
In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological…
- Trial name
- NCT06660446
- Testing
- Exercise
- Where
- 3 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Biogipuzkoa Health Research Institute
Breast Cancer
Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients
Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.
- Trial name
- NCT01168505
- Testing
- ferric hydroxide saccharate
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Chemotherapy Adjuvant, Breast Cancer
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant chemotherapy regimens.
- Trial name
- NCT01831024
- Testing
- Dignicap System
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Target Health Inc.
Breast Neoplasms, Adjuvant
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer.
- Conditions
- Breast Neoplasms, Adjuvant, Chemotherapy
- Trial name
- NCT00525642
- Testing
- Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 603 people
- Sponsor
- Fudan University
Esophagus Cancer
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
This is a single-arm, open, exploratory clinical study to evaluate the efficacy and safety of camrelizumab combined with chemotherapy for adjuvant treatment of nodal positive thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT05637268
- Testing
- Camrelizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Cancer
A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel is effective and safe in the treatment of high risk postoperative endometrial cancer patients.
- Trial name
- NCT00373620
- Testing
- paclitaxel
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Gynecologic Oncology Group
HIV Infections
Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
The purpose of this study is to see whether or not an HIV vaccination will help the body control the amount of HIV virus in blood (viral load) in patients who are not taking anti-HIV medicines.
- Trial name
- NCT00021762
- Testing
- HIV-1 Immunogen, Structured Treatment Interruption
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumors
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
This study is an open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.
- Trial name
- GUARDIAN-02 (NCT07351903)
- Testing
- GK01 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
The investigators propose to evaluate eribulin as adjuvant therapy in breast cancer patients who have residual invasive disease in breast or lymph node tissue following standard neoadjuvant chemotherapy and surgery regimen.
- Trial name
- NCT01401959
- Testing
- Eribulin, Trastuzumab
- Where
- 18 sites in United States
- Volunteers
- 127 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer Stage IV
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
The purpose of this research is to assess the safety profile and clinical benefit of Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast cancer
- Trial name
- NCT05033925
- Testing
- FADA (active fraction of Ficus septica leaf) 800 mg/day, FADA (active fraction of Ficus septica leaf) 2000 mg/day
- Where
- Indonesia
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Gadjah Mada University
Breast Cancer
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
The goal of this study is to increase our understanding of the adjuvant chemotherapy experience in older and younger adults by prospectively describing the longitudinal trajectory of functional status, comorbidity, and quality of…
- Trial name
- NCT01030250
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- City of Hope Medical Center
Triple Negative Breast Cancer, Breast Cancer
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from…
- Trial name
- NCT04768426
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.